ALLR (Allarity Therapeutics) Buyback Yield %: 3.69 (As of Jul. 01, 2026)


ALLR Allarity Therapeutics Inc ALLR
26 GF Score
Price $1.32
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics Buyback Yield %?

Allarity Therapeutics ALLR +3.10% 26 Buyback Yield % is 3.69 as of Jul. 01, 2026. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 745 Biotechnology companies, Allarity Therapeutics ranks better than 97.85% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Allarity Therapeutics's current buyback yield was 3.69%.

Allarity Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics Buyback Yield % Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial 0.00 0.00 -510.95 -437.17 -61.31

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -303.85 -123.55 -59.41 -61.31 4.39

ALLR vs NCEL, LPCN, PTN: Buyback Yield % Comparison

For the Biotechnology subindustry, Allarity Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allarity Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Buyback Yield % falls into.


ALLR
26GF Score
Allarity Therapeutics Inc ALLR
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Allarity Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-3.19 + 13.838) / 17.36748
=-61.31%

Allarity Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-3.452 + 2.695) / 17.24271
=4.39%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 3.69 mean?
Allarity Therapeutics (ALLR) has a Buyback Yield % of 3.69 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Allarity Therapeutics and its competitors. According to the industry distribution chart, Allarity Therapeutics ranks #16 out of 745 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Allarity Therapeutics' Buyback Yield % too high?
Allarity Therapeutics' current Buyback Yield % is 3.69. Based on the distribution chart, Allarity Therapeutics ranks #16 out of 745 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' Buyback Yield % compare to NCEL and LPCN?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #16 out of 745 companies for Buyback Yield %. This places Allarity Therapeutics in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current Buyback Yield % is 3.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current Buyback Yield % of 3.69. The current Buyback Yield % is 3.69. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current Buyback Yield % is 3.69 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score

Get the complete analysis for ALLR

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price